Caricamento...
Angiopoietin-like protein 3 blocks nuclear import of FAK and contributes to sorafenib response
BACKGROUND: Poor drug response of sorafenib is a major challenge which reduces clinical benefit of renal cell carcinoma (RCC) patients. It is therefore of great clinical significance to elucidate the underlying mechanism to restore the therapeutic response to sorafenib. METHODS: Angiopoietin-like pr...
Salvato in:
| Pubblicato in: | Br J Cancer |
|---|---|
| Autori principali: | , , , , , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Nature Publishing Group UK
2018
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6134083/ https://ncbi.nlm.nih.gov/pubmed/30033448 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41416-018-0189-4 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|